Acumen Pharmaceuticals (ABOS) News Today $1.31 -0.08 (-5.76%) Closing price 04:00 PM EasternExtended Trading$1.35 +0.04 (+3.13%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Lowered to $9.00 at Bank of AmericaAugust 27 at 1:09 PM | marketbeat.comAcumen Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 26 at 4:00 PM | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $9.00 by Analysts at Bank of AmericaAugust 26 at 2:11 AM | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) Shares Down 3.5% - Time to Sell?August 24, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Forecast for ABOS EarningsAugust 17, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Outlook for ABOS EarningsAugust 17, 2025 | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPSAugust 13, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comAcumen Pharmaceuticals’ Q2 2025 Financial and Strategic UpdateAugust 12, 2025 | tipranks.comEarnings Scheduled For August 12, 2025August 12, 2025 | benzinga.comAcumen Pharmaceuticals Reports Q2 Financial Results and InnovationsAugust 12, 2025 | msn.comAcumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comAcumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 12, 2025 | globenewswire.comAcumen Pharmaceuticals (ABOS) Expected to Announce Earnings on TuesdayAugust 6, 2025 | marketbeat.comAcumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025August 5, 2025 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Trading 5.8% Higher - Here's WhyJuly 31, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery ...July 15, 2025 | finanznachrichten.deJCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology PlatformJuly 15, 2025 | businesswire.comAcumen Pharmaceuticals to Present Findings on Sabirnetug at ... - NasdaqJuly 12, 2025 | nasdaq.comAcumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025July 10, 2025 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Trading Up 4.3% - Still a Buy?July 9, 2025 | marketbeat.comAcumen Pharmaceuticals Inc News (ABOS) - Investing.comJuly 2, 2025 | investing.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Increase in Short InterestJune 17, 2025 | marketbeat.comCitigroup Begins Coverage on Acumen Pharmaceuticals (NASDAQ:ABOS)June 17, 2025 | marketbeat.comBrokers Issue Forecasts for ABOS FY2026 EarningsJune 11, 2025 | marketbeat.comMillennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)June 2, 2025 | marketbeat.comFY2025 EPS Estimates for ABOS Reduced by Cantor FitzgeraldMay 21, 2025 | marketbeat.comAcumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug developmentMay 15, 2025 | seekingalpha.comAcumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comAcumen Pharmaceuticals (NASDAQ:ABOS) Issues Earnings Results, Beats Estimates By $0.46 EPSMay 15, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comAcumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...May 14, 2025 | finance.yahoo.com3ABOS : A Preview Of Acumen Pharmaceuticals's EarningsMay 12, 2025 | benzinga.comAcumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.comAcumen Pharmaceuticals to Participate in the Bank of America Healthcare ConferenceMay 7, 2025 | globenewswire.comAcumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025May 6, 2025 | globenewswire.comJPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)April 28, 2025 | marketbeat.comRock Springs Capital Management LP Trims Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)April 23, 2025 | marketbeat.comFranklin Resources Inc. Has $5.63 Million Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)April 13, 2025 | marketbeat.comAcumen presented results from pTau217 assay in Phase 2 ALTITUDE-AD trialApril 3, 2025 | markets.businessinsider.comAcumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual MeetingApril 2, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for ABOS FY2029 Earnings?March 31, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | seekingalpha.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comUBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00March 29, 2025 | marketbeat.comAcumen Pharmaceuticals (NASDAQ:ABOS) Price Target Lowered to $11.00 at HC WainwrightMarch 29, 2025 | marketbeat.comQ4 2024 Acumen Pharmaceuticals Inc Earnings CallMarch 29, 2025 | uk.finance.yahoo.comAcumen price target lowered to $11 from $15 at H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)March 29, 2025 | markets.businessinsider.comAcumen Pharmaceuticals’ Earnings Call: Progress Amid ChallengesMarch 28, 2025 | tipranks.com Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABOS Media Mentions By Week ABOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABOS News Sentiment▼0.110.99▲Average Medical News Sentiment ABOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABOS Articles This Week▼62▲ABOS Articles Average Week Get the Latest News and Ratings for ABOS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Acumen Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies INBX News Today ADCT News Today CTMX News Today ALDX News Today BNTC News Today TNXP News Today FDMT News Today AMRN News Today ZYBT News Today CADL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABOS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access